Literature DB >> 15168076

[Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation].

S E Baldus1, S P Mönig, W Schröder, R Metzger, S Lang, T K Zirbes, J Thiele, R P Müller, H P Dienes, A H Hölscher, P M Schneider.   

Abstract

Following surgical resection locally advanced oesophageal carcinomas exhibit a bad prognosis and therefore neoadjuvant therapeutic strategies were developed. Because success of therapy is associated with the extent of tumor regression in this context, the introduction of objective histopathological criteria seems to be very important. This study included 67 patients with oesophageal carcinomas (cT2-cT4 cNx cM0) that were treated with a cisplatin- and 5-fluorouracil-containing simultaneous radiochemotherapy. In 43 patients squamous cell, in 24 cases adenocarcinomas were diagnosed. After completion of therapy, a surgical resection and a histopathological examination of the tissue specimens were performed. The extent of tumor regression was histologically evaluated and therapy-induced alterations were graded semiquantitatively. Thereby, a significantly favorable prognosis was observed in the group of patients that showed a regression of carcinomas of 90% or more. Additionally, the extent of a resorptive-histiocytic reaction, giant cells and lymphocytic infiltrates correlated with the grade of regression. These results underline the importance of an exact examination and histomorphological evaluation of the response for the assessment of survival probability after neoadjuvant radiochemotherapy of oesophageal carcinomas.

Entities:  

Mesh:

Year:  2004        PMID: 15168076     DOI: 10.1007/s00292-004-0697-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

1.  P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer.

Authors:  G Esposito; S Pucciarelli; R Alaggio; L Giacomelli; E Marchiori; G A Iaderosa; M L Friso; P Toppan; L Chieco-Bianchi; M Lise
Journal:  Ann Surg Oncol       Date:  2001-05       Impact factor: 5.344

2.  Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression.

Authors:  Y Kajiyama; K Hattori; N Tomita; T Amano; Y Iwanuma; K Narumi; H Udagawa; M Tsurumaru
Journal:  Dis Esophagus       Date:  2002       Impact factor: 3.429

3.  [The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer].

Authors:  R M Hermann; R Krech; J Hartlapp; E Esser; B Christoph; M K Müller; W Wagner
Journal:  Strahlenther Onkol       Date:  2001-06       Impact factor: 3.621

4.  Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.

Authors:  D J Adelstein; T W Rice; M Becker; M A Larto; T J Kirby; A Koka; M Tefft; G Zuccaro
Journal:  Cancer       Date:  1997-09-15       Impact factor: 6.860

5.  A pathologic assessment of tumor residue and stromal changes after intraarterial chemotherapy for head and neck carcinomas. A study on serial sections of the whole surgical specimen.

Authors:  S Sulfaro; S Frustaci; R Volpe; L Barzan; R Comoretto; S Monfardini; A Carbone
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

6.  Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma: effect on tumor cell microinvolvement of regional lymph nodes.

Authors:  K Becker; U Fumagalli; J D Mueller; U Fink; J R Siewert; H Höfler
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

7.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

8.  Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer.

Authors:  Daisuke Satomi; Nobuhiro Takiguchi; Keiji Koda; Kenji Oda; Hirofumi Suzuki; Jun Yasutomi; Hiroshi Ishikura; Masaru Miyazaki
Journal:  Int J Oncol       Date:  2002-06       Impact factor: 5.650

9.  Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Thomas Papadopoulos; Marc Bigalke; Klaus Günther; Christoph Schick; Andrea Peters; Rolf Sauer; Franz Rödel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

Review 10.  Locally advanced esophageal cancer.

Authors:  Carol A Sherman; Andrew T Turrisi; Michael B Wallace; Carolyn E Reed
Journal:  Curr Treat Options Oncol       Date:  2002-12
View more
  15 in total

1.  Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

Authors:  Ralf Metzger; Ute Warnecke-Eberz; Hakan Alakus; Fabian Kütting; Jan Brabender; Daniel Vallböhmer; Peter P Grimminger; Stefan P Mönig; Uta Drebber; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

2.  [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].

Authors:  A-K Müller; C Lenschow; D Palmes; N Senninger; R Hummel; K Lindner
Journal:  Chirurg       Date:  2015-09       Impact factor: 0.955

3.  ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.

Authors:  Ute Warnecke-Eberz; Daniel Vallböhmer; Hakan Alakus; Fabian Kütting; Georg Lurje; Elfriede Bollschweiler; Anke Wienand-Dorweiler; Uta Drebber; Arnulf H Hölscher; Ralf Metzger
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

Review 4.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

5.  Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Ann Transl Med       Date:  2019-09

Review 6.  [Regression grading in gastrointestinal tumors].

Authors:  I Tischoff; A Tannapfel
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

7.  [Atypical tumor regression].

Authors:  B Heitplatz; K-M Müller
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 8.  Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.

Authors:  L E Salnikova; D S Kolobkov
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

Review 9.  [Carcinoma of the esophagus, esophagogastric junction, and stomach. Cooperation between pathology and surgery].

Authors:  A H Hölscher; U K Fetzner
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

10.  Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.

Authors:  Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.